Energy balance

GLP-1 receptor agonists (semaglutide) significantly improve quality of life and exercise capacity in obese patients with heart failure with preserved ejection fraction (HFpEF), primarily through substantial weight loss.

For obese patients with HFpEF, GLP-1 agonists like semaglutide are effective at improving quality of life and exercise capacity, largely by driving significant weight loss (approx. 13%). While these drugs are promising, their benefits appear closely tied to weight reduction rather than unique cardiac mechanisms. Therefore, they should be viewed as one option among others, including caloric restriction and supervised exercise, which may offer similar benefits at a lower long-term cost.